Seattle, WANCT05997615Now EnrollingIRB Ready

Hormone-refractory Prostate Cancer Clinical Trial in Seattle, WA

Access cutting-edge hormone-refractory prostate cancer treatment through this clinical trial at a research site in Seattle. Study-provided care at no cost to qualified participants.

Sponsored by Vir Biotechnology, Inc.

Quick Self-Assessment

See if you qualify for this Seattle location

Preparing your pre-screening questions…

Expert Care in Seattle

Access hormone-refractory prostate cancer specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related hormone-refractory prostate cancer treatment provided free

Apply for This Seattle Location

Check if you qualify for this hormone-refractory prostate cancer clinical trial in Seattle, WA

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to Seattle

    Convenient for WA residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit Seattle site if eligible
  4. 4Begin participation

About This Hormone-refractory Prostate Cancer Study in Seattle

The study will be conducted in 4 parts and will commence with dose escalation of VIR-5500 as a monotherapy (Part 1), followed by combination escalation (Part 3a), monotherapy dose expansion (Part 2) and combination dose expansion (Part 4a). * Part 1 (Monotherapy Dose Escalation): Single-agent VIR-5500 dose escalation * Part 2 (Monotherapy Dose Expansion): Single-agent VIR-5500 dose expansion * Part 3 (Combination Dose Escalation): VIR-5500 plus another therapeutic agent dose escalation Part 3a (Combination Dose Escalation): VIR-5500 in combination with an androgen receptor signaling inhibitor (ARSI) * Part 4 (Combination Dose Expansion): VIR-5500 plus another therapeutic agent dose expansion Part 4a (Combination Dose Expansion): VIR-5500 in combination with an androgen receptor signaling inhibitor (ARSI)

Sponsor: Vir Biotechnology, Inc.

Who Can Participate

Inclusion Criteria

Applicable to Parts 1 and 2
Have metastatic disease, defined by ≥ 1 metastatic lesion that is present on baseline computed tomography (CT), magnetic resonance imaging (MRI), or bone scan imaging
Have documented progressive mCRPC based on ≥ 1 of the criteria (per PCWG3)
PSA level ≥ 1 ng/mL that has increased on ≥ 2 successive occasions ≥ 1 week apart
Nodal or visceral progression as defined by RECIST v1.1 with PCWG3 modifications
Appearance of ≥ 2 new lesions in bone scan
Have been treated with ≥ 1 second-generation androgen-signaling inhibitor, including abiraterone, apalutamide, darolutamide, and/or enzalutamide
Have been treated with ≥ 1 prior taxane regimens (e.g., docetaxel, cabazitaxel)
Are deemed unsuitable for standard of care Applicable to Part 2, 3a and Part 4a,
Have metastatic CRPC, defined by ≥ 1 metastatic lesion that is present on baseline CT, MRI, or bone scan imaging that has documented progressive disease (PD) based on ≥ 1 of the following criteria (per PCWG3):
PSA level ≥ 1 ng/mL that has increased on ≥ 2 successive occasions ≥ 1 week apart
Nodal or visceral progression as defined by RECIST v1.1 with PCWG3 modifications
Appearance of ≥2 new lesions in bone scan
Participants with metastatic hormone sensitive prostate cancer (mHSPC) or with biochemical recurrent prostate cancer (BRPC) may also participate in select cohorts of this clinical trial.

Exclusion Criteria

Presence of dominant histopathological features representative of sarcomatoid, spindle cell, or neuroendocrine small cell components
Has acute or chronic infections
Has a concomitant medical or inflammatory condition that may increase the risk of toxicity to VIR-5500 (AMX-500), per the Investigator
Has lesions in proximity of vital organs
Has known active CNS metastases and/or carcinomatous meningitis The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Seattle?

Yes, this clinical trial (NCT05997615) has an active research site in Seattle, WA that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Hormone-refractory Prostate Cancer Treatment Options in Seattle, WA

If you're searching for hormone-refractory prostate cancer treatment options in Seattle, WA, this clinical trial (NCT05997615) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Seattle research site is actively enrolling participants for this clinical trial. You'll receive care from experienced hormone-refractory prostate cancer specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all hormone-refractory prostate cancer clinical trials near you to find additional studies recruiting in your area.

More Prostate Cancer Trials in Seattle, WA

See all prostate cancer clinical trials recruiting in Seattle — not just this study.

Browse Prostate Cancer Trials in Seattle →

Browse More Trials by Condition

Prostate Cancer TrialsRheumatoid Arthritis TrialsAll Conditions →

Ready to Join in Seattle?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · Seattle, WA